Dr. Mehmet Oz, the Republican nominee in Pennsylvania's crucial U.S. Senate race, has repeatedly criticized pharmaceutical companies blamed for the rising cost of insulin — but his recent financial disclosure shows that he has invested up to $715,000 in exactly those companies.
Prior to announcing his Senate bid, Oz repeatedly railed about the rising cost of diabetes treatment, lamenting in a Newsmax op-ed that the cost of insulin had more than tripled over the past decade.
